Pharmacokinetics of Staccato ® alprazolam in healthy adult participants in two phase 1 studies: An open‐label smoker study and a randomized, placebo‐controlled ethnobridging study
Epilepsia · 2024
DOI: 10.1111/epi.17901 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Epilepsia, 2024. Verfasst von Yoshinobu Hayakawa und 5 weiteren Autor:innen. Beteiligte Einrichtung: UCB Pharma, Tokyo, Japan. Hauptthemen laut MEDLINE: Alprazolam, Smokers. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB Pharma.
Abstract (Originalsprache)
Objective
Staccato ® alprazolam is a single‐use, drug–device combination delivering alprazolam to the deep lung that is being evaluated as treatment for rapid and early seizure termination. This article reports pharmacokinetic (PK) data from two phase 1 studies of Staccato alprazolam in healthy adult participants.
Methods
The smoker study (EPK‐002/NCT03516305) was an open‐label, nonrandomized, single‐dose, PK study in smokers and nonsmokers aged 21–50 years, administered a single inhaled dose of 1 mg Staccato alprazolam. The ethnobridging study (UP0101/NCT04782388) was a double‐blind, placebo‐controlled study in Japanese, Chinese, and Caucasian participants aged 18–55 years randomized 4:1 to a single inhaled dose of Staccato alprazolam 2 mg or Staccato placebo.
Results
In the smoker study, 36 participants (18 smokers, 18 nonsmokers) were enrolled and received Staccato alprazolam. Following Staccato administration, alprazolam was rapidly absorbed, with a median time to peak drug plasma concentration ( T max ) of 2 min in both smokers (range = 2–30 min) and nonsmokers (range = 2–60 min). Staccato alprazolam was rapidly absorbed to a similar extent in both smokers and nonsmokers. The most commonly reported treatment‐emergent adverse events (TEAEs) were somnolence and dizziness. In the ethnobridging study, 10 participants each of Japanese, Chinese, and Caucasian ethnicities were randomized 4:1 to Staccato alprazolam or Staccato placebo. Following Staccato administration, alprazolam was rapidly absorbed and distributed, with a median T max of 1.5–2 min in Japanese (range = 1–2 min), Chinese (range = 1–34 min), and Caucasian (range = 1–120 min) participants. Somnolence and sedation were the most commonly reported TEAEs. In both studies, there were no deaths, and no participants reported serious or severe TEAEs, or discontinued due to TEAEs. Significance Alprazolam was rapidly absorbed, and therapeutic drug levels were achieved within 2 min postdose when administered to the lung with the Staccato device. Staccato alprazolam was generally well tolerated and displayed a safety profile consistent with that known from other alprazolam applications. No new safety signals were identified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCB Pharma, Tokyo, Japan.
- UCB Pharma, Braine-l'Alleud, Belgium.
- UCB Pharma, Smyrna, Georgia, USA.
- UCB Pharma, Monheim am Rhein, Germany.
ORCID-Profile: Hugues Chanteux
Förderung
- UCB Pharma
Zitieren
APA
Hayakawa, Y., Rospo, C., Bartmann, A. P., King, A., Roebling, R., & Chanteux, H. (2024). Pharmacokinetics of Staccato ® alprazolam in healthy adult participants in two phase 1 studies: An open‐label smoker study and a randomized, placebo‐controlled ethnobridging study. Epilepsia. https://doi.org/10.1111/epi.17901
Vancouver
Hayakawa Y, Rospo C, Bartmann AP, King A, Roebling R, Chanteux H. Pharmacokinetics of Staccato ® alprazolam in healthy adult participants in two phase 1 studies: An open‐label smoker study and a randomized, placebo‐controlled ethnobridging study. Epilepsia. 2024. doi:10.1111/epi.17901
BibTeX
@article{Hayakawa2024,
author = {Hayakawa, Yoshinobu and Rospo, Chiara and Bartmann, Ana Paula and King, Aliceson and Roebling, Robert and Chanteux, Hugues},
title = {Pharmacokinetics of Staccato ® alprazolam in healthy adult participants in two phase 1 studies: An open‐label smoker study and a randomized, placebo‐controlled ethnobridging study},
journal = {Epilepsia},
year = {2024},
doi = {10.1111/epi.17901}
}
EUVIMED